Incidence and Risk Factors of Acute Kidney Injury in Patients Receiving Concomitant Vancomycin and Continuous-Infusion Piperacillin/Tazobactam: A Retrospective Cohort Study.

Published in: The Annals of pharmacotherapy (2020)

The incidence of AKI for VPT-CI found in this study was comparable to that found with intermittent and extended-infusion piperacillin/tazobactam with concomitant vancomycin in prior literature. Additional research should further analyze risk factors for the development of AKI for patients on concomitant vancomycin and piperacillin/tazobactam therapy.

Keyphrases

methicillin resistant staphylococcus aureus
acute kidney injury
end stage renal disease
gram negative
low dose
ejection fraction
prognostic factors
stem cells
high intensity
multidrug resistant
staphylococcus aureus